News

March 18, 2020March 27, 2020

Novo Nordisk Pauses 3 Clinical Trials of Concizumab Amid Safety Concerns

News

Novo Nordisk has paused three clinical trials evaluating concizumab, its experimental treatment candidate for hemophilia A and B, due to safety concerns. The three Explorer studies — the Phase 2 ... Read more

March 16, 2020March 16, 2020

New Gene Therapy Shows Promise in Hemophilia A Mouse Model, Study Shows

News

Cells derived from hemophilia A patients — genetically reprogrammed to produce a functional clotting factor VIII (FVIII) that’s missing or not working in people with the blood disease — ... Read more

March 13, 2020March 13, 2020

Kovaltry Safe and Effective Prophylactic for Hemophilia A, Long-term Study Shows

News

Preventive treatment with Kovaltry (octocog alfa) is safe and effective at preventing bleeds, including joint bleeds, for up to two years in people with hemophilia A, a long-term extension ... Read more

March 11, 2020March 11, 2020

Young Children, Parents Struggle Socially and Emotionally, Survey Finds

News

Struggles with “mood and emotions” and feelings of social isolation or inadequate social support are more pronounced in young children with hemophilia and their parents than in age-matched healthy ... Read more

March 9, 2020March 9, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 9, 2020March 9, 2020

ClotChip, Portable Way of Analyzing Blood’s Ability to Clot, Named Breakthrough Device

News

ClotChip, a portable device designed to quickly assess the ability of a person’s blood to clot, has been designated a breakthrough device by the U. S. Food and Drug Administration ... Read more

March 6, 2020March 6, 2020

In Potential $100M Deal, Medexus Acquires Ixinity for Hemophilia B

News

In an agreement expected to exceed $100 million, Medexus Pharmaceuticals has bought global commercial rights to Ixinity, an approved recombinant factor IX therapy for hemophilia B previously marketed by Aptevo ... Read more

March 4, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the ... Read more

March 4, 2020March 4, 2020

Patients With Bleeding Disorders Given Global Voice in PPTA Awareness Campaign

News

In support of Bleeding Disorders Awareness Month in March, the Plasma Protein Therapeutics Association (PPTA) is providing a global outlet for patients who wish to share their experiences, advocate for therapy ... Read more

March 2, 2020March 2, 2020

Elsevier Opens Books, Review Articles to Rare Disease Researchers Starting Feb. 29

News

Beginning on Feb. 29, Rare Disease Day, chapters from notable scientific books and clinical review articles covering rare disorders will be available free-of-charge from Elsevier. The offer runs through April 30, ... Read more

Pin It on Pinterest